As we observed significantly increased circulating IL-10 levels in pancreatic cancer patients, compared to the controls, here, we assessed the influence of IL-10 blockade on MSLN-specific T cell responses in 9 pancreatic disease patients. The gene discussed is IL10; the disease is pancreatic neoplasm.